ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Hutchison And Lilly Expand Collaboration

by Jean-François Tremblay
December 1, 2008 | APPEARED IN VOLUME 86, ISSUE 48

Shanghai-based Hutchison MediPharma and Eli Lilly & Co. have agreed to expand their R&D collaboration. Under the new pact, Lilly will provide another oncology target and Hutchison will assume primary responsibility for the identification and selection of suitable clinical drug candidates. Hutchison will get up-front payments, as well as option fees, milestone payments, and royalties on global sales of any resulting drug. Lilly and Hutchison formed their first such pact in August 2007.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment